Two Sigma Advisers
PYXS icon

Two Sigma Advisers’s Pyxis Oncology PYXS Stock Holding History

Two Sigma Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,624
Closed -$26K – 1642
2025
Q4 		$26K Sell
22,624
-29,900
-57% -$105K ﹤0.01% 2305
2025
Q3 		$117K Buy
+52,524
New +$75.7K ﹤0.01% 2214
2024
Q3 		– Sell
-14,100
Closed -$46.7K – 2477
2024
Q2 		$46.7K Sell
14,100
-1,500
-10% -$6.31K ﹤0.01% 2371
2024
Q1 		$66.5K Sell
15,600
-48,600
-76% -$204K ﹤0.01% 2331
2023
Q4 		$116K Sell
64,200
-16,300
-20% -$27.9K ﹤0.01% 2310
2023
Q3 		$160K Buy
80,500
+55,700
+225% +$129K ﹤0.01% 2137
2023
Q2 		$63.5K Buy
+24,800
New +$78.7K ﹤0.01% 2250
2022
Q4 		– Sell
-10,400
Closed -$20K – 2654
2022
Q3 		$20K Buy
+10,400
New +$27.2K ﹤0.01% 2443

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's PYXS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 22,624 shares — an estimated $26K sold.

Two Sigma Advisers first reported a position in PYXS in Q3 2022 and held it in 8 quarters. The position peaked at $160K in Q3 2023. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 22,624 Pyxis Oncology shares in Q1 2026, an estimated $26K.
  • Two Sigma Advisers first reported a position in Pyxis Oncology in Q3 2022 and held it in 8 quarters.
  • Two Sigma Advisers's Pyxis Oncology position peaked at $160K in Q3 2023.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.